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Abstract Thrombin-related peptide 508 (TP508) acceler-
ates bone regeneration during distraction osteogenesis
(DO). We have examined the effect of TP508 on bone
regeneration during DO by immunolocalization of Runx2
protein, a marker of osteoblast differentiation, and of
osteopontin (OPN) and bone sialoprotein (BSP), two late
markers of the osteoblast lineage. Distraction was per-
formed in tibiae of rabbits over a period of 6 days. TP508
(30 or 300 μg) or vehicle was injected into the distraction
gap at the beginning and end of the distraction period. Two
weeks after active distraction, tissue samples were harvested
and processed for immunohistochemical analysis. We also
tested the in vitro effect of TP508 on Runx2 mRNA
expression in osteoblast-like (MC3T3-E1) cells by polymer-
ase chain reaction analysis. Runx2 and OPN protein were
observed in preosteoblasts, osteoblasts, osteocytes of newly
formed bone, blood vessel cells and many fibroblast-like
cells of the soft connective tissue. Immunostaining for BSP
was more restricted to osteoblasts and osteocytes. Signifi-
cantly more Runx2- and OPN-expressing cells were seen in
the group treated with 300 μg TP508 than in the control
group injected with saline or with 30 μg TP508. However,
TP508 failed to increase Runx2 mRNA levels significantly
in MC3T3-E1 cells after 2–3 days of exposure. Our data
suggest that TP508 enhances bone regeneration during DO
by increasing the proportion of cells of the osteoblastic
lineage. Clinically, TP508 may shorten the healing time
during DO; this might be of benefit when bone regeneration
is slow.
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Introduction
Distraction osteogenesis (DO) is a well-established tech-
nique, originally developed in orthopedic surgery for bone
lengthening (Kojimoto et al. 1988) and later also used to
treat hereditary malformations in the craniomaxillofacial
region (Amir et al. 2006). DO is characterized by the
formation of new bone between two osteotomized bone
segments, which are separated by gradual traction. One of
the clinical phases of the distraction technique is the bone
consolidation period, defined as the time between the end
of active distraction and the removal of the distraction
device. It represents the time needed for a complete
bridging of the distraction gap by bone and a further
maturation of this bone. Typically, the bone consolidation
phase takes approximately 6–12 weeks in the craniomax-
illofacial region and 3–6 months in long bones (Fischgrund
et al. 1994;S m i t he ta l .1999; Felemovicius et al. 2000;
Amir et al. 2006). Although DO is believed to be superior
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Belfast, UKto other bone augmentation techniques, many attempts
have been made to improve the technique to enhance the
bone regeneration process in the distraction gap (Hagiwara
and Bell 2000;L ie ta l .2002; Mofid et al. 2002;T a k a m i n e
et al. 2002; Schortinghuis et al. 2005). Such improvements
would provide the opportunity to shorten the bone
consolidation period and hence minimize complications
such as the development of non-union, infection or
fracture. Various methods have been tested to promote
bone formation in the distraction gap, e.g. electrical and
mechanical stimulation (Hagiwara and Bell 2000;M o f i d
et al. 2002), transplantation of osteoblast-like cells (Takamine
et al. 2002) or administration of growth factors such as
bone morphogenetic proteins (Li et al. 2002) or fibroblast
growth factor 2 (FGF-2; Okazaki et al. 1999). Another
procedure to accelerate bone regeneration involves the
application of thrombin-related peptide 508 (TP508; Ryaby
et al. 2000; Sheller et al. 2004;L ie ta l .2005a, b;W a n ge ta l .
2005).
TP508 is a synthetic peptide consisting of 23 amino
acids, which represent the natural amino acid sequence of
the receptor-binding domain of human thrombin (pro-
thrombin amino acids 508–530; Sower et al. 1999;
Stiernberg et al. 2000). Thrombin is an important factor in
blood homeostasis, inflammation and wound healing
(Coughlin et al. 1992). It plays a role in the formation of
fibrin clots and platelet activation. Thrombin also stimulates
the cell proliferation, migration and/or differentiation of
various cell types, such as fibroblasts, endothelial cells and
lymphocytes. All these cell types contain one or more
thrombin receptors (Chen and Buchanan 1975; Belloni
et al. 1992). TP508 appears to mimic and accelerate many
of the effects of native thrombin in initiating wound healing
through a non-proteolytic pathway (Sower et al. 1999).
Histological studies have indicated that TP508 is chemo-
tactic for neutrophils, lymphocytes and monocytic cells; it
enhances the formation of granulation tissue, neovasculari-
zation and other wound-healing events (Sower et al. 1999;
Ryaby et al. 2000; Naldini et al. 2004).
TP508 has also been tested for its potential to enhance
bone formation (Ryaby et al. 2000; Sheller et al. 2004;L i
et al. 2005a, b;W a n ge ta l .2005). A single injection of
1 μg TP508 accelerates fracture healing in rat long bone
fracture. The breaking strength of bones of young and
aged rats injected with TP508 has been enhanced over that
of controls (Ryaby et al. 2000). One recent study of TP508
treatment during DO has revealed a significantly greater
bone mineral density in TP508-treated groups than in
saline-treated controls (Li et al. 2005a, b). Histological
analysis has also shown advanced bone consolidation and
remodeling after TP508 treatment.
In the present study, we report the effect of TP508 in
the regulation of bone regeneration during DO in more
detail. We have examined Runx2/Cbfa1, osteopontin
(OPN) and bone sialoprotein (BSP) protein expression in
tissue sections of rabbit long bones undergoing DO.
Runx2 is an essential transcription factor for osteoblast
differentiation and for extracellular matrix gene expression
(Komori et al. 1997; Karsenty et al. 1999). In Runx2
knockout mice, both intramembranous and endochondral
ossification are blocked because of the maturational arrest
of osteoblasts (Komori et al. 1997). Runx2 can directly
stimulate the transcription of the collagen type I and
osteoblast-related genes, such as those for OPN and BSP,
both major non-collagenous proteins found in the extracel-
lular matrix of bone (Karsenty et al. 1999). We have
hypothesized that TP508 treatment during DO enhances the
expression of Runx2, OPN and BSP.
Materials and methods
Animal model of DO
The paraffin blocks containing distracted rabbit long bones
were those prepared previously (Li et al. 2005a, b) from 30
adult male New Zealand White rabbits (age 24 weeks, body
weight 2.6–3.5 kg). External fixators were applied to
stabilize the osteotomized mid-tibia for 7 days of the
latency period and were activated for 6 days, once a day at
a rate of 1.4 mm. This distraction rate was intentionally
chosen in order to copy the poor bone healing condition as
previously described (Li et al. 1997).
During the experiment, seven animals were excluded in
the study because of soft tissue complications (n=2),
pinhole fracture (n=3) and anaesthetic death (n=2). The
remaining 23 rabbits were randomly divided into three
experimental groups, each group consisting of minimally
seven rabbits. TP508 (OrthoLogic, Tempe, USA) at two
different concentrations (30 and 300 μg TP508) or saline
were injected percutanously at the beginning and at the
end of the lengthening phase. The first group (n=8)
received injections of 300 μl saline containing 300 μg
TP508, the second group (n=8) received injections of
300 μl saline containing 30 μg TP508 and the third group
(n=7) received injections of 300 μl saline alone and
served as a control group. The injections were given in
three different areas (100 μl in each area): the proximal,
central and distal area of the distraction gap. Two weeks
after the lengthening phase, all animals were killed. Tissue
samples consisting of the distraction gap and 5 mm
proximal and distal to the pre-existing bone were then
harvested and immediately fixed in 95% ethanol for
further examination. Tissues were decalcified with EDTA
and embedded in paraffin. Serial sections (5 μmt h i c k )
36 Cell Tissue Res (2007) 330:35–44were cut and mounted on poly-lysine-coated glass slides.
The peripheral quantitative computed tomography and
histological examination of these bones has been pub-
lished previously (Li et al. 2005a, b).
All animal experimental procedures were approved and
performed following the guidelines for animal scientific
procedures (Animal Scientific Procedures Act 1986, British
Home Office).
Antibodies
The mouse recombinant monoclonal antibody Pebp2al-
phaA was kindly donated by Dr. K. Sasaguri, Kanawaga
Dental School, Japan. This antibody has been used and
characterized previously and reacts with all isotypes of
Runx2 (Bronckers et al. 2001, 2005). The mouse anti-rat
OPN monoclonal antibody (MPIIIB101) was obtained
from the Developmental Studies Hybridoma Bank (devel-
oped under the auspices of the NICHD and maintained by
the University of Iowa, Department of Biological Sciences
Iowa City, IA 52242, USA). The mouse anti-human BSP
(monoclonal antibody A4232.1) was purchased from
Immunodiagnostik, Bensheim, Germany. Both anti-OPN
and anti-BSP antibodies have been used and specified
previously (Ibrahim et al. 2000; Bronckers et al. 2005;
Zerbo et al. 2005).
Immunohistochemical procedures
Tissue sections were de-paraffinized in xylene and
rehydrated through a graded series of aqueous ethanol
solutions. Endogenous peroxidase was quenched by
incubation in 3% H2O2 in 100% ethanol (5 min). A pre-
incubation in hot citrate buffer (0.01 M, pH 6.0, 95°C,
20 min) was performed for antigen retrieval prior to
incubation with 30% normal horse serum (30 min).
Sections were then incubated overnight with primary
monoclonal anti-Runx2 antibody (1:200), anti-BSP anti-
body (1:400) or anti-OPN antibody (1:600) at 4°C in a
humidifiedchamber. After washes with phosphate-buffered
saline (PBS), biotinylated horse anti-mouse IgG (ABC-
peroxidase Elite kit; Vector Laboratories, Burlingame,
Calif., USA) was added at a dilution of 1:200 and the
sections were incubated at room temperature for a mini-
mum of 60 min. The sections were washed again with PBS,
incubated with ABC peroxidase complex for another
60 min followed by a maximum of 20 min in 3,3′
diaminobenzidine substrate solution (Vectastain kit) to
visualize the immunoreaction, counterstained with methyl
green for 2–3 min, mounted in 50% glycerol and covered
with a glass coverslip. As negative controls, sections were
incubated with non-immune mouse IgG in place of the
primary antibody.
Scoring
Sections were examined by using a Leica DM RA
microscope equipped with a Leica DC 200 digital camera.
The central areas of the gap were selected as the region of
interest (ROI). First, the boundaries of the distraction gap
(indicated by the osteotomy lines) were determined and
subsequently a grid was positioned over the ROI halfway
between the two osteotomy lines. The grid was 609 μmi n
width and 479 μm in length. The ROI consisted of some
n e w l yf o r m e db o n e( m o s t l yi nt h eg r o u pt r e a t e dw i t h
300 μg TP508) and fibrous tissue (Fig. 1a). Counting was
performed by using the grid at a magnification of 200×,
with a minimum of three sections, at least 30 μma p a r t ,
per animal. Some tissue blocks were of poor quality or no
longer contained a complete intact gap area with an ROI;
this reduced the number of animals per group to 5–6
animals. The total number of cells was counted (immuno-
positive and immunonegative cells). The sections were
coded and randomized. Quantification was performed by
one investigator (L.A.) who was unaware of the origin of
the sections. Numbers of immunopositive cells were noted
in absolute terms and were expressed as the percentage of
all (immunopositive and negative) cells present in the
ROI.
Cell cultures
The mouse osteoblast-like MC3T3-E1 cell line, derived
from newborn mouse calvaria, was routinely maintained
in α-MEM (Gibco, Paisley, UK) supplemented with 10%
fetal bovine serum (HyClone), 120 μg/ml penicillin
( S i g m a ,S tL o u i s ,M o . ,U S A ) ,1 0 0μg/ml streptomycin
sulphate (Sigma), 1.25 μg/ml fungizone (Gibco), 50 μg/ml
sodium ascorbate (Merck, Darmstadt, Germany), 10 mM
β-glycerophosphate (Sigma) and 300 μg/ml glutamine
(Sigma) at 37°C in a humidified atmosphere of 5% CO2 in
air. This cell line is capable of expressing Runx2 mRNA
(Tsuji et al. 1998). To stimulate cells to express osteo-
blastic markers, they were first exposed to 10 nM
dexamethasone in 25 cm
2 flasks (Greiner BioOne,
Solingen, Germany) for 1 week. Upon confluency (typi-
cally after 5 days), cells were harvested by using 0.25%
trypsin and 0.1% EDTA in PBS, centrifuged at 600g for
10 min, washed and plated in 24-well culture dishes
(Greiner BioOne) at three different cell densities (3×10
4,
1.5×10
4 and 7.5×10
3 cells/well) in order to obtain a
comparable number of cells at the end of each experiment.
After 1 day of culture, the medium was replaced by media
containing various concentrations of TP508 (0, 10 or
100 μg/ml). Throughout the experiment, all media were
supplemented with 10 nM dexamethasone. Cells were
e x p o s e dt oT P 5 0 8f o r2 4 ,4 8a n d7 2h ,a f t e rw h i c ht i m e s ,
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quadruplicate and repeated once.
RNA analysis and quantitative real-time polymerase chain
reaction
Total RNA from cultured cells was isolated by using
TRIZOL reagent (Gibco) according to the manufacturer’s
instructions. The RNA content was determined by measur-
ing the absorbance in water at 260 nm by means of an
Ultrospec III spectrophotometer (Amersham, Buckingham-
shire, England). cDNA synthesis was performed by using
750 ng total RNA in a final reaction volume of 20 μl
containing 5 U transcriptor (Roche Applied Science), 5×
polymerase chain reaction (PCR) buffer, 4 U random
primers (Roche), 20 U protector RNase inhibitor (Roche),
1 mmol each dNTP and 10 μl template. The reverse
transcription step was performed on a Gene Amp 9700
Thermocycler (Applied Biosystems, Foster City, Calif.,
USA) at 55°C for 30 min followed by 85°C for 5 min.
Real-time PCR was performed on the ABI PRISM 7700
sequence detection system (Applied Biosystems). The
phosphobilinogen deaminase gene (PBGD) served as the
endogenous reference (de Vries et al. 1999) to normalize
Runx2 expression. The primers for the amplification of
Runx2 mRNA were 5′-ATGCTTCATTCGCCTCAC-3′ and
5′-ACTGCTTGCAGCCTTAAAT-3′ (GenBank database,
accession no. NM 001024630). The PCR primers for
PBGD, amplified as the internal reference, were 5′-
AGTGATGAAAGATGGGCAACT-3′ and 5′-TCTGGAC
CATCTTCTTGCTGA-3′ (accession no. BC 003861). For
the amplification of the Runx2 and PBGD products,
37.5 ng cDNA was added to the PCR mixture containing
SYBR Green PCR Master Mix consisting of SYBR Green I
Dye, AmpliTaq Gold DNA polymerase, dNTPs with dUTP,
a passive reference and buffer (Applied Biosystems) and
300 nM of each primer, in a final volume of 25 μl. The
enzyme was activated by preheating the samples for 10 min
at 95°C, followed by a two-step PCR procedure consisting
of a denaturation step at 95°C for 15 s and an annealing and
extension step at 60°C for 1 min for 45 cycles. Relative
expression was calculated by using the comparative Ct
method. Samples were normalized for the expression of
PBGD by calculating ΔCt (CtRunx2−CtPBGD); subsequently,
the ΔΔCt values were calculated as ΔCtsample−ΔCtcalibrator ,
where the calibrator was the control sample (without TP508
incubation). Relative expression of the Runx2 gene was
expressed as 2
-(ΔΔ Ct) (Livak and Schmittgen 2001).
Statistical analysis
Values obtained from the scoring of tissue sections and
normalized mRNA levels determined by PCR analysis
(presented as means and standard deviations) were analysed
by using GraphPad Prism 4 for Windows. For the analysis
of the immunostaining, an average value was calculated per
animal for each protein and treatment; these average values
were used to determine the mean and standard deviation for
each treatment group (5–6 animals/group). Analysis of
variance (ANOVA) was used to test for statistical signifi-
cance, which was accepted when P<0.05 (two-tailed).
Tukey’s post test was performed to compare individual
pairs of groups if P<0.05. Linear regression analysis was
used to examine the correlation between Runx2 mRNA
expression and culture time.
Results
Immunohistochemistry demonstrated different localization
patterns for Runx2, OPN and BSP proteins. Cells expressing
these proteins were detected throughout the distraction gap
and in the periosteum, the periosteal callus and the old
(predistraction)bone(Fig.1a). Runx2 staining was located in
nuclei and cytoplasm, whereas strong staining for OPN and
BSP was localized in the cytoplasm (Figs. 1b,c,2i,3c); weak
staining for BSP and OPN was also seen in the extracellular
bone matrix. Figures 1, 2, 3 present the different staining
patterns and Table 1 summarizes the average intensity of
immunostaining in the ROI.
Expression of Runx2, OPN and BSP in the group injected
with saline (control group) was similar to that in the group
treated with 30 μg TP508 (Figs. 1d, 2a–f). The intensity of
the staining in both groups was however much lower than
that in the 300 μg TP508 group (Figs. 1c,2g,h,3c,d). Runx2
and OPN were detected in active osteoblasts, in fibroblasts
next to the osteoblastic layer (presumably pre-osteoblasts),
in osteocytes in the old (predistraction) and newly formed
bone, in fibroblasts of the periosteum, in the central area of
the gap, in endothelial and smooth muscle cells of the
vessels and in chondrocyte-like cells next to new bone. We
found two types of cartilage-like tissue in the group treated
with 30 μg TP508 and in control group, i.e. fibrocartilage-
like (collagen fibres between lacunae) and hypertrophic-like
(evenly dispersed chondrocytes, without clear fibres;
Fig. 1d). Higher numbers of cells associated with these
two tissues were found in the group treated with 30 μg
TP508 and in the control group than in the group treated
with 300 μg TP508 (Fig. 2a,d,g). More fibrocartilage-like
cells than hypertrophic cartilage-like cells were positive for
Runx2 (Fig. 1d). Sections in which primary antibodies had
been replaced with non-immune antibodies were negative
(Fig. 1e).
The Runx2- and OPN-positive blood vessel cells (both
the endothelial and smooth muscle cells) were more evident
in the group with 300 μg TP508 (Fig. 3a,b). They appeared
38 Cell Tissue Res (2007) 330:35–44to occur at locations with high bone formation activity.
Connective tissue cells in close vicinity to Runx2-positive
blood vessels also stained faintly for Runx2 but not for
OPN. Immunostaining for BSP was more restricted than
that for Runx2 and OPN and was seen in osteoblasts and
young osteocytes (Fig. 3c,d). Weak expression was found
in some of the cells considered to be pre-osteoblasts.
Fibroblast-like cells in the central fibrous area of the
Fig. 1 Immunolocalization of Runx2 and osteopontin proteins in
TP508-treated groups (a-c, e 300 μg TP508 group, d 30 μg TP508
group). a Overview of immunoreactions in a biopsy taken from rabbit
long bone after distraction osteogenesis Runx2 staining (FT fibrous
tissue, NB new bone, P periosteum, PC periosteal callus). A white grid
was used to count the number of immunopositive and negative cells in
the region of interest. ×50. b Runx2 staining in the nuclei and cytoplasm
of the cells. Runx2 was strongly expressed in osteoblasts (Ob). Note that
young osteocytes (Ocy), which had recently embedded in the bone
matrix, expressed Runx2 protein. Cells adjacent to the osteoblast layer,
presumably pre-osteoblasts (Pre-Ob), also expressed Runx2, but with
lower intensity (B bone). ×400. c Immunostaining for osteopontin.
Positive staining was found in the cytoplasm of the cells (white arrows).
Note that expression was stronger towards the newly formed bone (NB).
×200. d Runx2 immunostaining in tissue of a rabbit injected with 30 μg
TP508. Expression was much lower than that after injection with
300 μg TP508 and was similar to saline-injected control tissue (not
shown). Fewer fibrocartilage-like cells (FCC) were stained than after
injection with 300 μgT P 5 0 8( HC hypertrophic cartilage-like cells).
×200. e Negative control stained with non-immune IgG instead of
primary antibodies to Runx2. Note the lack of positive staining.
Counter-staining with methyl green. ×200. Bars 20 μm( b, d),
50 μm( c, e), 300 μm( a)
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(Fig. 2b,e,h) but were negative for BSP. The number and
the intensity of Runx2 and OPN in the gap increased from
fibrous tissue towards the newly formed bone (Fig. 1c).
Weak BSP staining was seen in the area within the gap in
which bone trabecules started to be formed (Fig. 2c,f,i).
In the group injected with 300 μg TP508, immunostain-
ing for Runx2, OPN and BSP was distributed throughout
the regenerating areas. The immunostaining for Runx2,
OPN and BSP in the connective tissue in the gap (endosteal
area) was relatively high and as intense as in the periosteal
callus tissue. In the 30 μg TP508 group and in the control
Fig. 2 Runx2 (a, d, g), OPN (b,
e, h) and BSP (c, f, i) expression
in the distraction gap (B bone,
FT fibrous tissue, FC fibrous
cartilage-like tissue, asterisks
central area of distraction gap,
hatch layers of cells adjacent to
the newly formed bone, arrows
osteoblasts, arrowheads osteo-
cytes) of the various groups (a-c
0 μg TP508 group, d-f 30 μg
TP508 group, g-i 300 μg TP508
group). Inset (i): Newly formed
bone in the gap. Original mag-
nifications: a 50×; d, g 100×; b,
e, h 100×; c, f, i, inset 200×.
Bars 20 μm( c, f, i), 50 μm( b,
d, e, g, h), 100 μm( a)
Fig. 3 Immunolocalization of
Runx2, OPN and BSP in the
300 μg TP508 group. a Runx2
staining of a vessel wall (EC
endothelial cells, SMC smooth
muscle cells). Note that some
cells near the blood vessel
weakly express Runx2 (white
arrows). ×400. b Osteopontin
staining of a vessel wall. Note
that the cells surrounding the
blood vessel are immunonega-
tive and only stain weakly for
methyl green (white arrows).
×400. c BSP staining is restrict-
ed to the layer of osteoblasts
(Ob) and hardly occurs in fi-
brous tissue × 400. d OPN
staining is expressed in osteo-
blasts (Ob) and osteocytes of
new bone (NB) and some fi-
brous tissue cells close to
osteoblasts, presumably pre-
osteoblasts (Pre-Ob). ×200.
Bars 20 μm( b), 50 μm( c, d),
100 μm( a)
40 Cell Tissue Res (2007) 330:35–44group, staining was less intense in the central gap area than
in the periosteal callus area.
Quantitative immunohistochemistry was performed to
investigate the effect of TP508 injection on the total
number of cells and on the number of differentiated bone
cells in the central area of the gap. The total number of cells
(immunostained and unstained) in the ROI was not
significantly different between the three groups. Mean
values and the standard deviation of the total number of
cells in the tissues treated with 0, 30 μg TP508 and 300 μg
TP508 were 958±217, 1140±137 and 1161±282, respec-
tively (ANOVA, P=0.5). This indicated that TP508 injection
had no overall effect on total number of cells in the
distraction gap. Next, we counted the number of cells, in
the ROI, expressing each of the three antibodies tested.
Absolute values of immunopositive cells in the 0, 30 μg
TP508 and 300 μg TP508 groups were as follows: for
Runx2, 263±61, 288±171, 560±115, respectively; for OPN,
299±201,244±40,677±216,respectively;forBSP,255±111,
252±73, 480±31, respectively. We also expressed the
number of immunopositive cells as a percentage of the total
number of cells (Fig. 4). The number of Runx2- and OPN-
expressing cells was significantly higher in the group
treated with 300 μg TP508 than in the control group that
received only saline (P<0.05; Fig. 4). The number of BSP-
expressing cells was also higher in the 300 μg TP508 group
than in the 30 μg TP508 group (P<0.05). No significant
differences were found between the 30 μg TP508 group
and the control group receiving saline (P>0.05).
The previous data suggested that TP508 increased the
differentiation of osteogenic cells into osteoblasts in situ.
To determine whether TP508 had any direct effect on
osteogenic cells that were in the process of turning into
osteoblasts, we performed in vitro experiments with the
(mouse) osteoblast-cell line MC3T3-E1 after pre-culture in
the presence of dexamethasone. After a 24-h stimulation
with TP508, we found a significant (but slight) down-
regulation of Runx2 mRNA at 10 μg/ml TP508 (P=0.008)
but no change at 100 μg/ml TP508 (Fig. 5).
Discussion
This study demonstrates a positive effect of TP508 on the
synthetic activity of bone-forming cells in the distraction
Fig. 4 Effect of TP508 injection on the number of immunopositive
cells in the central portion of the distraction gap (black bars Runx2-
positive cells, grey bars OPN-positive cells, white bars BSP-positive
cells). Data are presented as percentage cells immunopositive for each
of the three proteins examined (means±SD). *The percentages of
Runx2-, OPN- and BSP-positive cells in the 300 μg TP508 group
were significantly higher than for cells with the corresponding
proteins in the saline-treated control group; the percentage of BSP-
positive cells in the 300 μg group was also significantly higher than
that in the 30 μg group (ANOVA, P<0.05).
Fig. 5 Quantitative reverse transcription/polymerase chain reaction
analysis of Runx2 mRNA expression in mouse osteoblast-like
(MC3T3-E1) cells cultured for 24, 48 and 72 h in the presence of
TP508 (black bars control group with 0 μg/ml TP508, hatched bars
10 μg/ml TP508, white bars 100 μg/ml TP508). Data are presented as
means±SD (n=8) and are representative of two experiments. *The
10 μg/ml TP508 group at 24 h of incubation was significantly lower
than the control group (one-way ANOVA; Tukey’s multiple compar-
ison test, P<0.01). Correlation analysis between mRNA and culture
time: r
2=0.94, P=0.06 for 10 μg/ml TP508; r
2=0.99, P=0.06 for
100 μg/ml TP508
Table 1 Intensity scores of immunostaining in region of interest (± weak, + moderate, ++ strong, +++ very strong). The intensity of
immunostaining was scored in the central area of the gap (region of interest) at 40× final magnification. Variation exists between sections in each
animal and between animals within groups
Marker Group with 0 μg TP508 Group with 30 μg TP508 Group with 300 μg TP508
RUNX2 + to ++ + to ++ ++ to +++
OPN ± to ++ ± to + +++
BSP ± to +++ ± + to +++
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TP508, significantly more cells expressing Runx2, OPN
and BSP are located in the central part of the distraction
gap, predominantly consisting of soft connective tissue. We
have also found that these cells stain more intensely for
Runx2, OPN and BSP suggesting that TP508 not only
proportionally increases the number of osteogenic cells in
the distraction gap but also their expression level. The
finding that TP508 enhances bone-forming activity in the
soft tissue gap area is in agreement with previous
morphometric data indicating that TP508 stimulates bone
regeneration in the distraction gap (Li et al. 2005a, b).
The underlying molecular mechanism of the stimulation
of Runx2 expression in the distraction gap after TP508
treatment is not clear. Our in vitro experiment with
osteoblast-like MC3T3-cells suggests that TP508 does not
have a significant positive effect on Runx2 mRNA.
However, we cannot rule out that the MCT3C3 cells are
too far advanced along the osteoblast differentiation
pathway to respond to TP508 for they had been pre-
cultured in dexamethasone-containing medium before they
were exposed to TP508. No definitive conclusions can
therefore be drawn from these in vitro data. In vivo, TP508
may have stimulated the differentiation of osteogenic cells
though the activity of other non-osteogenic cell types.
Injection of TP508 into a bone fracture model upregulates
FGF-2 mRNA in (not further specified) tissues at the
fracture site (Wang et al. 2005). Since FGF-2 is known to
be an upstream regulator of Runx2 (Franceschi and Xiao
2003), one explanation for the increased Runx2 expression
in the gap is via an enhanced cytokine release by
inflammatory cells, which in turn stimulates osteoblast
differentiation (Okazaki et al. 1999; Stiernberg et al. 2000;
Franceschi and Xiao 2003; Naldini et al. 2004). Alterna-
tively, TP508 stimulates blood vessel growth in vivo
(Norfleet et al. 2000; Li et al. 2005a, b; Vartanian et al.
2005; Wang et al. 2005) and this subsequently enhances
bone formation. TP508 increases recruitment of human
aortic and microvascular endothelial cells through chemo-
taxis (Norfleet et al. 2000; Li et al. 2002), upregulates
angiogenesis-related genes (Wang et al. 2005) and acts
directly on microvascular cells to accelerate sprouting
(Vartanian et al. 2005). Vascularization provides the oxygen
that is required for the metabolic activity of the osteoblasts
(Tuncay et al. 1994; Salim et al. 2004); it provides homes
for circulating stem cells that, under proper stimulation,
differentiate into osteoblastic cells (Kuznetsov et al. 2001).
In addition, vessel cells secrete paracrine factors that can
regulate bone cell metabolism (Villars et al. 2000; Street
et al. 2002). Thus, the angiogenic properties of TP508
might help to enhance bone growth.
In the present study, we have also found Runx2 protein
expression in endothelial cells, vascular smooth muscle
cells and loose connective cells surrounding developing
blood vessels at sites of active bone and tissue formation.
Recent studies have presented evidence for transient Runx2
mRNA and protein expression during angiogenesis in
embryonic human orofacial tissues (Bronckers et al.
2005), in human primary bone marrow endothelial cells
and in endothelial cell lines (Namba et al. 2000; Sun et al.
2001). Thus, our data suggest that, with respect to Runx2
expression, the formation of blood vessels in regenerating
adult tissues during DO resembles vessel formation in
embryonic tissues. Of note, under certain conditions such as
inflammation, cells associated with vessels (e.g. pericytes,
endothelial cells and smooth muscle cells) or their
precursors are capable of differentiating into osteoblast-like
cells (Schor et al. 1995; Reilly et al. 1998; Kinner and
Spector 2002) suggesting that the forming microvasculature
is a potential source for osteogenic cells.
The distribution and staining intensity of Runx2, OPN
and BSP varies between the different groups. In the control
group and in the group treated with a low dose of TP508,
staining is more pronounced in the periosteal callus than in
the tissue in the distraction gap. However, in the group
treated with a high dose of TP508, we have found the same
high staining in both periosteal callus and gap tissue.
Periosteal callus formation is a common finding during
fracture healing (Gerstenfeld et al. 2003). New woven bone
is formed rapidly around the fractured segments, because of
stimulation of the periosteum that contains many osteopro-
genitor cells. In the same section, a high staining intensity
in the periosteal callus can therefore be considered as an
internal reference. Hence, as the staining for Runx2, OPN
and BSP in the distraction gap is as intense as that in the
periosteal callus at the high dose of TP508, this is a clear
indication that the high dose of TP508 stimulates bone
formation in the distraction gap. This observation is in
accordance to a previous histological study that has
demonstrated advanced bone consolidation in a group
treated with a high dose of TP508 (Li et al. 2005b).
TP508 might stimulate the migration of osteoblast precur-
sors to the distraction gap (Li et al. 2005a). Li and
colleagues have shown that human periosteal-derived
osteoblasts and human microvascular endothelial cells are
chemotactic to TP508 (Li et al. 2005a). Therefore, the
presence of TP508 in the gap might attract osteoprogenitor
cells in the periosteum to migrate into the distraction gap.
Runx2 is a critical gene for osteoblast differentiation and
for the function of the fully differentiated osteoblast
(Komori et al. 1997; Karsenty et al. 1999). The Runx2
protein binds to the osteoblast-specific element 2 that is
present in the promoter regions of all major extracellular
matrix genes expressed in osteoblasts, including the genes
for osteocalcin (OC), OPN and BSP and it regulates the
expression of these proteins (Karsenty et al. 1999). OPN
42 Cell Tissue Res (2007) 330:35–44and BSP belong to the Small Integrin-Binding LIgand, N-
linked Glycoprotein (or SIBLING) family (Fisher et al.
2001). Among other functions, members of this family are
known to have a role in mineralization, as they bind
strongly to hydroxyapatite (Fisher et al. 2001).
In conclusion, we have demonstrated that the increase of
bone regeneration by thrombin-related peptide TP508 is
associated with an increase in the immunostaining for Runx2,
an essential transcription factor of the osteoblastic lineage,
and for the bone matrix proteins BSP and OPN. TP508 may
thus be a candidate for enhancing bone regeneration when
bone regeneration is slow, as occurs in elderly patients.
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